BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

Impact · against what's priced in

BridgeBio's positive Phase 3 PROPEL 3 data for oral infigratinib establishes a potential best-in-class profile for achondroplasia, specifically through superior growth velocity and unique proportionality benefits. The concrete regulatory timeline for late 2026 submissions and a 2027 launch provides a clear path to commercialization and potential PRV value.

BBIO+0.70

No priced-in read yet